Aeglea BioTherapeutics Inc.

Aeglea BioTherapeutics Inc. - Company Overview

Company Overview ... Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with ...

Aeglea BioTherapeutics Inc. - Press Releases

Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria.

Aeglea BioTherapeutics Announces Name Change to Spyre ...

(NASDAQ: AGLE) (the "Company" or "Spyre"), a development-stage biotechnology company, today announced its name change to Spyre Therapeutics, Inc ...

Spyre Therapeutics

Engineering For New Heights in the Treatment of Inflammatory Bowel Disease.

Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with ...

Aeglea BioTherapeutics - LinkedIn

Aeglea BioTherapeutics | 9887 followers on LinkedIn. With its acquisition of Spyre Therapeutics ... Paragon Therapeutics, Inc. Biotechnology.

Aeglea BioTherapeutics Inc. - Financials - Quarterly Results

Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update · The Company continues preclinical development efforts on a ...

Aeglea BioTherapeutics Inc. - Events & Presentations

... Aeglea BioTherapeutics Inc. to send you the requested Investor Email Alert updates. * Required. Email Address *. Investor Alert Options *. News. Events ...

Spyre Therapeutics, Inc. | Investor Relations - Company Overview

Spyre Therapeutics is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products.

Aeglea Biotherapeutics - BioSpace

Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics

(“Aeglea”) (NASDAQ: AGLE), today announced it has completed the acquisition of Spyre Therapeutics, Inc. (“Spyre”), a privately held ...

Aeglea BioTherapeutics Inc. - Resources - Investor FAQs

Where is Aeglea BioTherapeutics' corporate headquarters? Aeglea BioTherapeutics is headquartered at 805 Las Cimas Parkway, Suite 100, Austin, TX 78746.

Aeglea BioTherapeutics Company Profile 2024 - PitchBook

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products.

Working at Aeglea Biotherapeutics Inc: 3 Reviews - Indeed

Decent employer ... Aeglea has good working environment. I like my coworkers, they are good people. They have good products and technologies. They ...

Aeglea BioTherapeutics - Crunchbase Company Profile & Funding

Legal Name Aeglea BioTherapeutics, Inc. ... Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic ...

AEGLEA BIOTHERAPEUTICS, INC.

The accompanying notes are an integral part of these condensed consolidated financial statements. 1. Page 6. Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Inc. - BioCentury Company Profiles - BCIQ

Aeglea BioTherapeutics Inc. Headquarters: Austin, TX, United States of America. Website: N/A.

Aeglea BioTherapeutics Announces Sale of Pegzilarginase to ...

Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential ...

Aeglea BioTherapeutics, Inc. Contracts & Agreements | Justia

Search Aeglea BioTherapeutics, Inc. business contracts filed with the Securities and Exchange Commission.

Aeglea BioTherapeutics Inc. (NASD:AGLE) : Articles - Law360

The latest litigation news involving the company Aeglea BioTherapeutics Inc. (NASD:AGLE)